Shares have slumped 60% since the Wall Street Journal reported in April that the company was preparing to file for bankruptcy ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

Super Micro Computer’s guidance for its fiscal fourth quarter misses analysts’ estimates, Advanced Micro Devices tops ...

The Fed slashed rates by 1% through 2024, but has signaled a much slower pace of easing in 2025. The quarterly earnings ...

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Novo Nordisk trades for ...

From new scientific data-sharing initiatives to US drug tariffs, May brought a range of major news to the pharma landscape.

Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...

Stock futures rose on Wednesday on optimism around trade talks with China. Treasury Secretary Scott Bessent and Trade Representative Jamieson Greer are slated to meet with Chinese officials for the ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025. | As ...